MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s12072-021-10250-2

Медицинская библиотека · Hepatology international · 2021

Immunotherapy of HBV-related advanced hepatocellular carcinoma with short-term HBV-specific TCR expressed T cells: results of dose escalation, phase I trial.

Meng Fanping, Zhao Jinfang, Tan Anthony Tanoto, Hu Wei, Wang Si-Yu, Jin Jiehua, Wu Juan, Li Yuanyuan, Shi Lei, Fu Jun-Liang, Yu Shuangjie, Shen Yingjuan, Liu Limin, Luan Junqing, Shi Ming, Xie Yunbo, Zhou Chun-Bao, Wong Regina Wanju, Lu-En Wai, Koh Sarene, Bertoletti Antonio, Wang Tingting, Zhang Ji-Yuan, Wang Fu-Sheng

Клиническое исследование I фазыСтатьяПеревод в очереди

Аннотация

BACKGROUND & AIMS: Immunotherapy with hepatitis B virus (HBV)-specific TCR redirected T (HBV-TCR-T) cells in HBV-related hepatocellular carcinoma (HBV-HCC) patients after liver transplantation was reported to be safe and had potential therapeutic efficacy. We aim to investigate the safety of HBV-TCR-T-cell immunotherapy in advanced HBV-HCC patients who had not met the criteria for liver transplantation.

METHODS

We enrolled eight patients with advanced HBV-HCC and adoptively transferred short-lived autologous T cells expressing HBV-specific TCR to perform an open-label, phase 1 dose-escalation study (NCT03899415). The primary endpoint was to evaluate the safety of HBV-TCR-T-cell therapy according to National Cancer Institute Common Terminology Criteria for Adverse Events (version 4.03) during the dose-escalation process. The secondary endpoint was to assess the efficacy of HBV-TCR-T-cell therapy by evaluating the anti-tumor responses using RECIST criteria (version 1.1) and the overall survival.

RESULTS

Adverse events were observed in two participants among the 8 patients enrolled. Only one patient experienced a Grade 3 liver-related adverse event after receiving a dose of 1 × 105 HBV-TCR-T cells/kg, then normalized without interventions with immunosuppressive agents. Among the patients, one achieved a partial response lasting for 27.7 months. Importantly, most of the patients exhibited a reduction or stabilization of circulating HBsAg and HBV DNA levels after HBV-TCR-T-cell infusion, indicating the on-target effects.

CONCLUSIONS

The adoptive transfer of HBV-TCR-T cells into advanced HBV-HCC patients were generally safe and well-tolerated. Observations of clinical efficacy support the continued development and eventual application of this treatment strategy in patients with advanced HBV-related HCC.

CLINICAL TRIALS REGISTRATION: This study was registered at ClinicalTrials.gov (NCT03899415).

Для цитирования: Meng Fanping, Zhao Jinfang, Tan Anthony Tanoto, Hu Wei, Wang Si-Yu, Jin Jiehua, Wu Juan, Li Yuanyuan, Shi Lei, Fu Jun-Liang, Yu Shuangjie, Shen Yingjuan, Liu Limin, Luan Junqing, Shi Ming, Xie Yunbo, Zhou Chun-Bao, Wong Regina Wanju, Lu-En Wai, Koh Sarene, Bertoletti Antonio, Wang Tingting, Zhang Ji-Yuan, Wang Fu-Sheng. Immunotherapy of HBV-related advanced hepatocellular carcinoma with short-term HBV-specific TCR expressed T cells: results of dose escalation, phase I trial.. Hepatology international. 2021. DOI: 10.1007/s12072-021-10250-2.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.